September 2007
• Celtic Pharma portfolio company, IDEA AG, signs major licensing agreement with Alpharma Inc.
June 2007
• Celtic Pharma and Neurobiological Technologies report updated results from long-term open-label extension study for Xerecept, and its clinical development status
April 2007
• Celtic Pharma receives IND approval to initiate a large randomized study in the US for TA-NIC, its immunotherapy vaccine for the treatment of smoking cessation.
February 2007
• Celtic Pharmaceutical Holdings L.P. Raises $156 Million in Debt, Bringing Total Capital to over $400 Million
• Celtic Pharma Terminates Transmid™ Trial Ksb311R/Ciii/001
November 2006
• Celtic Pharma appoints two new senior executives
• XERECEPT® Update Presented at Society for Neuro-Oncology Meeting
August 2006
• Celtic Pharma Notes Progress By IDEA AG
June 2006
• Celtic Pharma Reports Preliminary Results Of Phase 2 Clinical Trials With TA-CD, Cocaine Addiction Vaccine
May 2006
• Michael Earl joins
April 2006
• Reinaldo Diaz joins
• Fulcrum Pharma alliance signed
February 2006
• IDEA AG license acquired
• XERECEPT® 2nd Phase III trial started
November 2005
• Xerecept® license completed
• Dr. Patrick O'Connor joins
September 2005
• Stake in IDEA AG acquired
• Xerecept® license acquired
• Xenova acquisition completed
• CMIC alliance announced
June 2005
• Fund announced
Celtic Pharma Announces Strategic Partnership Between Ipsen and Inspiration Biopharmaceuticals
January 21, 2010
Celtic Pharmaceutical Holdings L.P. (“Celtic Pharma”) today announced the formation of a strategic partnership between Ipsen and Inspiration Biopharmaceuticals (“Inspiration”) to create a world leading hemophilia franchise, an important milestone for the Celtic Pharma portfolio.
Read the full press release
Celtic Pharma Announces Results of a Phase III Program Evaluating XERECEPT® in Patients with Primary and Metastatic Brain Tumors
June 1, 2009
Administration of XERECEPT®in Patients with Cerebral Edema Demonstrated Clinically Significant Reductions in Steroid Usage Compared to Placebo.
New Preclinical Studies Indicate XERECEPT®May Have Direct Anti-Tumor and Angiogenesis Inhibition Activity.
Read the full press release
Celtic Pharma Announces Successful Outcome of Phase II Trial for Topical Treatment of Onychomycosis
March 26, 2009
Celtic Pharma announced the successful outcome of its Phase II trial of TDT-067, terbinafine in Transfersomes, for the treatment of onychomycosis.
Read the full press release
Celtic Pharma Announces Update on Status of XERECEPT® Program Sale Planned in 2009
December 16, 2008
Celtic Pharma announced that the databases have been locked and preliminary analyses completed on the two double-blinded studies of XERECEPT® (corticorelin acetate), as a treatment for peritumoral brain edema, as well as an initial database lock on the open-label study of XERECEPT’s long-term safety and efficacy.
Read the full press release
Celtic Pharmaceutical Holdings and Inspiration Biopharmaceuticals Forge Collaboration To Deliver Improved Therapies to Patients with Hemophilia B
January 9, 2008
Celtic Pharma and Inspiration Biopharmaceuticals, Inc. (Inspiration) announced that they have agreed to enter into a collaboration intended to enhance the development of Inspiration’s Factor IX for the treatment of Hemophilia B. Hemophilia B, the second most common type of hemophilia and a $650 million global market today, is largely an inherited disorder in which Factor IX, one of the proteins needed to form blood clots is missing or reduced. Inspiration’s development program is aimed at bringing more affordable, safe and effective therapeutic options to Hemophilia B patients and potentially providing treatment options that are less disruptive to their daily lives.
Read the full press release
Celtic Pharma Reports Data Presented at Society for Neuro-Oncology Annual Meeting and Provides Update on XERECEPT® Clinical Program
December 4, 2007
Celtic Pharma today reported interim study results for XERECEPT® (human corticotropin-releasing factor (hCRF)), which were presented at the 12th Annual Meeting of the Society for Neuro-Oncology ("SNO"), and provided an update on the XERECEPT® clinical development program.
Read the full press release
Celtic Pharma completes rapid enrollment in Phase IIB study for TA-NIC, the nicotine vaccine for smoking cessation
October 29, 2007
Celtic Pharma announces it has completed enrollment in a large Phase IIB clinical study in the US. Over 520 patients were recruited into the study in 10 weeks, significantly ahead of schedule.
Read the full press release
Celtic Pharma Announces Initiation of Phase II Clinical Trial for TDT-067, a Treatment for Onychomycosis
October 15, 2007
Celtic Pharma announced today the enrollment of the first patient into the Phase II trial of TDT-067, terbinafine in Transfersomes®, for the treatment of onychomycosis. This is an open-label study to explore the efficacy and safety of topically applied terbinafine delivered through the Transfersome® targeted delivery technology. Celtic Pharma acquired an exclusive global licence to IDEA AG’s Transfersome® technology in February 2006.
Read the full press release